Proatherogenic disturbances in lipoprotein profile, associated enzymes and transfer proteins in women with iron deficiency anaemia

Clinical Biochemistry

Volumn 43, Issue 4-5, 2010, Pages 416-423

  Meroño, Tomás ^a   Sorroche, Patricia ^b   Rosso, Leonardo A Gómez ^a   Casañas, Liliana ^b   Boero, Laura E ^a   Arbelbide, Jorge A ^b   Brites, Fernando D ^a  

^a University of Buenos Aires   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; Iron; Iron deficiency anaemia; Lipoprotein associated phospholipase A2; Oxidized LDL; Paraoxonase 1

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE 1; CARRIER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRANSFERRIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ERYTHROCYTE VOLUME; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WOMEN'S HEALTH;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANEMIA, IRON-DEFICIENCY; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HUMANS; LIPOPROTEINS; MIDDLE AGED;

EID: 77049118707     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.10.003     Document Type: Article

References (56)

1. Clark S.F. Iron deficiency anaemia. Nutr. Clin. Pract. 23 (2008) 128-141
2. Hentze M.W., Muckenthaler M.U., and Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 117 (2004) 285-297
3. WHO/UNICEF/UNU. Iron deficiency Anaemia: Assessment, Prevention and Control. A Guide for Programme Managers (2001), World Health Organization, Geneva. http://www.who.int/nutrition/publications/en/ida_assessment_prevention_c ontrol.pdf http://www.who.int/nutrition/publications/en/ida_assessment_prevention_c ontrol.pdf
4. Sarnak M.J., Tighiouart H., Manjunath G., et al. Anaemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J. Am. Coll. Cardiol. 40 (2002) 27-33
5. Chonchol M., and Nielson C. Haemoglobin levels and coronary artery disease. Am. Heart J. 155 (2008) 494-498
6. Archbold R.A., Balami D., Al-Hajiri A., et al. Haemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients. Am. Heart J. 152 (2006) 1091-1095
7. Isler M., Delibas N., Guclu M., et al. Superoxide dismutase and glutathione peroxidase in erythrocytes of patients with iron deficiency anaemia: effects of different treatment modalities. Croat. Med. J. 43 (2002) 16-19
8. Kurtoglu E., Ugur A., Baltaci A.K., and Undar L. Effect of iron supplementation on oxidative stress and antioxidant status in iron-deficiency anaemia. Biol. Trace Elem. Res. 96 (2003) 117-123
9. Sundaram R.C., Selvaraj N., Vijayan G., Bobby Z., Hamide A., and Rattina Dasse N. Increased plasma malondialdehyde and fructosamine in iron deficiency anaemia: effect of treatment. Biomed. Pharmacother. 61 (2007) 682-685
10. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004) 1381-1478
11. Aslan M., Kosecik M., Horoz M., Selek S., Celik H., and Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anaemia. Atherosclerosis 191 (2007) 397-402
12. Canales A., and Sánchez-Muniz F.J. Paraoxonase, something more than an enzyme?. Med. Clin. (Barc) 121 (2003) 537-548
13. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96 (1995) 2882-2891
14. Lagrost L., Gandjini H., Athias A., Guyard-Dangremont V., Lallemant C., and Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler. Thromb. 13 (1993) 815-825
15. Zeller M., Masson D., Farnier M., et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 13 50 (2007) 1948-1955
16. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 14 110 (2004) 1418-1423
17. Gómez Rosso L., Benítez M.B., Fornari M.C., et al. Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome. Atherosclerosis 199 (2008) 415-423
18. Brites F.D., Cavallero E., de Geitere C., et al. Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patients. Clin. Chim. Acta 279 (1999) 1-14
19. Brites F.D., Bonavita C.D., De Geitere C., et al. Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 152 (2000) 181-192
20. 2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 923-931
21. Qiao J., Huang F., Naikawadi R.P., Kim K.S., Said T., and Lum H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am. J. Physiol., Lung Cell Mol. Physiol. 291 (2006) L91-101
22. Zhou L., Shi M., Guo Z., Brisbon W., Hoover R., and Yang H. Different cytotoxic injuries induced by lysophosphatidylcholine and 7-ketocholesterol in mouse endothelial cells. Endothelium 13 (2006) 213-226
23. 2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur. Heart J. 30 (2009) 107-115
24. 2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 40 (2009) 376-381
25. Assmann G., Jabs H.U., Kohnert U., Nolte W., and Schriewer H. LDL (low-density-lipoprotein) cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. Clin. Chim. Acta 140 (1984) 77-83
26. Warnick G.R., Benderson J., and Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-densitylipoprotein cholesterol. Clin. Chem. 28 (1982) 1379-1388
27. Furlong C.E., Richter R.J., Seidel S.L., Costa L.G., and Motulsky A.G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal. Biochem. 180 (1989) 242-247
28. Blank M.L., Hall M.N., Cress E.A., and Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasmaacetylhydrolase: higher activities in hypertensive rats. Biochem. Biophys. Res. Commun. 113 (1983) 666-671
29. Go A.S., Yang J., Ackerson L.M., Lepper K., Robbins S., Massie B.M., et al. Haemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anaemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113 (2006) 2713-2723
30. Sorlie P.D., Garcia-Palmieri M.R., Costas Jr. R., and Havlik R.J. Haematocrit and risk of coronary heart disease: the Puerto Rico Health Program. Am. Heart J. 101 (1981) 456-461
31. Brown D.W., Giles W.H., and Croft J.B. Haematocrit and the risk of coronary heart disease mortality. Am. Heart J. 142 (2001) 657-663
32. Gagnon D.R., Zhang T.J., Brand F.N., and Kannel W.B. Haematocrit and the risk of cardiovascular disease-the Framingham Study: a 34-year follow-up. Am. Heart J. 127 (1994) 674-682
33. Astor B.C., Coresh J., Heiss G., Pettitt D., and Sarnak M.J. Kidney function and anaemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 151 (2006) 492-500
34. Rye K.A., and Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 421-428
35. McLaughlin T., Reaven G., Abbasi F., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am. J. Cardiol. 96 (2005) 399-404
36. Amine E.K., and Hegsted D.M. Iron deficiency lipemia in the rat and chick. J. Nutr. 101 (1971) 1575-1582
37. Sherman A.R. Serum lipids in suckling and post-weanling iron-deficient rats. Lipids 14 (1979) 888-892
38. Stangl G.I., and Kirchgessner M. Different degrees of moderate iron deficiency modulate lipid metabolism of rats. Lipids 33 (1998) 889-895
39. Yamagishi H., Okazaki H., Shimizu M., Izawa T., and Komabayashi T. Relationships among serum triacylglycerol, fat pad weight, and lipolysis in iron-deficient rats. J. Nutr. Biochem. 11 (2000) 455-460
40. Skrede S., and Seip M. Serum lipoproteins in children with anaemia. Scand. J. Haematol. 23 (1979) 232-238
41. Tanzer F., Hizel S., Cetinkaya O., and Sekreter E. Serum free carnitine and total triglycerid levels in children with iron deficiency anaemia. Int. J. Vitam. Nutr. Res. 71 (2001) 66-69
42. Hulse J.D., Ellis S.R., and Henderson L.M. Carnitine biosynthesis. beta-Hydroxylation of trimethyllysine by an alpha-ketoglutarate-dependent mitochondrial dioxygenase. J. Biol. Chem. 253 (1978) 1654-1659
43. Bartholmey S.J., and Sherman A.R. Carnitine levels in iron-deficient rat pups. J. Nutr. 115 (1985) 138-145
44. Citak E.C., Citak F.E., and Kurekci A.E. Serum carnitine levels in children with iron-deficiency anaemia with or without pica. Pediatr. Hematol. Oncol. 23 (2006) 381-385
45. Brites F.D., Bonavita C.D., Cloës M., et al. VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein. Clin. Chim. Acta 269 (1998) 107-124
46. Murakami T., Michelagnoli S., Longhi R., et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1819-1828
47. Guérin M., Le Goff W., Lassel T.S., Van Tol A., Steiner G., and Chapman M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 282-288
48. Lasunción M.A., Iglesias A., Skottová N., Orozco E., and Herrera E. High-density lipoprotein subpopulations as substrates for the transfer of cholesteryl esters to very-low-density lipoproteins. Biochem. J. 270 (1990 Sep 1) 441-449
49. Evans A.J., Wolfe B.M., Strong W.L., and Huff M.W. Reduced lipolysis of large apo E-poor very-low-density lipoprotein subfractions from type IV hypertriglyceridemic subjects in vitro and in vivo. Metabolism 42 (1993) 105-115
50. Glass C., Pittman R.C., Weinstein D.B., and Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 5435-5439
51. Ozdemir A., Sevinç C., Selamet U., Kamaci B., and Atalay S. Age- and body mass index-dependent relationship between correction of iron deficiency anaemia and insulin resistance in non-diabetic premenopausal women. Ann. Saudi Med. 27 (2007) 356-361
52. Guérin M., Egger P., Soudant C., et al. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J. Lipid Res. 43 (2002) 1652-1660
53. Nordestgaard B.G., Wootton R., and Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 534-542
54. Tzotzas T., Desrumaux C., and Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes. Rev. 10 4 (2009) 403-411
55. Dullaart R.P., de Vries R., Dallinga-Thie G.M., Sluiter W.J., and van Tol A. Phospholipid transfer protein activity is determined by type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clin. Endocrinol. (Oxf) 68 (2008) 375-381
56. Attia N., Domingo N., Lorec A.M., et al. Reverse modulation of the HDL anionic peptide factor and phospholipid transfer protein activity in coronary artery disease and type 2 diabetes mellitus. Clin. Biochem. 42 (2009) 845-851